Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease

Neurobiology of Disease

Volumn 43, Issue 3, 2011, Pages 663-668

  Armentero, Marie Therese ^a   Levandis, Giovanna ^a   Bazzini, Eleonora ^a   Cerri, Silvia ^a   Ghezzi, Cristina ^a   Blandini, Fabio ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

6 hydroxydopamine; Animal model; Complete Freund's adjuvant; ICAM; NCAM; Neurodegeneration; Neuroinflammation; PECAM; VCAM

Indexed keywords

CD31 ANTIGEN; FREUND ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; NERVE CELL ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE 1; OXIDOPAMINE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; INFLAMMATION; MALE; MESENCEPHALON; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

ANIMALS; ANTIGENS, CD31; CELL ADHESION MOLECULES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FREUND'S ADJUVANT; INTERCELLULAR ADHESION MOLECULE-1; MALE; NERVE DEGENERATION; NEURAL CELL ADHESION MOLECULES; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; SYMPATHOLYTICS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79960222209     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.05.017     Document Type: Article

References (39)

1. Akiyama H., Kawamata T., Imada T., Tooyama I., Ishii T., McGeer P. Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol. 1993, 85:628-634.
2. Armentero M.T., Fancellu R., Nappi G., Bramanti P., Blandini F. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol. Dis. 2006, 22:1-9.
3. Armentero M.T., Levandis G., Nappi G., Bazzini E., Blandini F. Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol. Dis. 2006, 24:492-505.
4. Bell M.D., Perry V.H. Adhesion molecule expression on murine cerebral endotelium following the injection of a proinflammagen or during acute neuronal degeneration. J. Neurocytol. 1995, 24:695-710.
5. Bileviciute I., Theodorsson E., Lundeberg T. Is the pretreatment effect of low dose Freund's adjuvant on adjuvant arthritis due to an activation of the nervous system?. Neuropeptides 1996, 30:405-411.
6. Blandini F., Levandis G., Bazzini E., Nappi G., Armentero M.T. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur. J. Neurosci. 2007, 25:397-405.
7. Blandini F., Armentero M.T., Martignoni E. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat. Disord. 2008, 14(Suppl 2):S124-S129.
8. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192.
9. Brooks T.A., Hawkins B.T., Huber J.D., Egleton R.D., Davis T.P. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Heart and Circulatory Physiology 2005, 289:H738-H743.
10. Brooks T.A., Ocheltree S.M., Seelbach M.J., Charles R.A., Nametz N., Egleton R.D., et al. Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain. Brain Res. 2006, 1120:172-182.
11. Bullard D., Hu X., Schoeb T., Collins R., Beaudet A., Barnum S. Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178:851-857.
12. Cao J., Wang H., Yu J., Yang H., Xiao C., Gao D. Involvement of NCAM in the effects of GDNF on the neurite outgrowth in the dopamine neurons. Neurosci. Res. 2008, 61:390-397.
13. Carta A.R., Kachroo A., Schintu N., Xu K., Schwarzschild M.A., Wardas J., et al. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 2009, 111:1478-1489.
14. Carvey P.M., Zhao C.H., Hendey B., Lum H., Trachtenberg J., Desai B.S., et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur. J. Neurosci. 2005, 22:1158-1168.
15. Chang R., Hudson P., Wilson B., Haddon L., Hong J. Influence of neurons on lipopolysaccharide-stimulated production of nitric oxide and tumor necrosis factor-alpha by cultured glia. Brain Res. 2000, 853:236-244.
16. Chao C., Ma Y., Chu K., Lee E. Integrin alphav and NCAM mediate the effects of GDNF on DA neuron survival, outgrowth, DA turnover and motor activity in rats. Neurobiol. Aging 2003, 24:105-116.
17. Cross R., Roszman T. Central catecholamine depletion impairs in vivo immunity but not in vitro lymphocyte activation. J. Neuroimmunol. 1988, 19:33-45.
18. Deleplanque B., Vitiello S., Le Moal M., Neveu P. Modulation of immune reactivity by unilateral striatal and mesolimbic dopaminergic lesions. Neurosci. Lett. 1994, 166:216-220.
19. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175:303-317.
20. Downer E.J., Cowley T.R., Lyons A., Mills K.H., Berezin V., Bock E., et al. A novel anti-inflammatory role of NCAM-derived mimetic peptide, FGL. Neurobiol. Aging 2010, 31:118-128.
21. Engler H., Doenlen R., C R, Engler A., Niemi M., Besedovsky H., et al. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease. Brain Behav. Immun. 2009, 23:518-526.
22. Feuerstein G.Z., Liu T., Barone F.C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc. Brain Metab. Rev. 1994, 6:341-360.
23. Frau L., Borsini F., Wardas J., Khairnar A.S., Schintu N., Morelli M. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. Synapse 2011, 65:181-188.
24. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394.
25. He Y., Appel S., Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 2001, 909:187-193.
26. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
27. Ibáñez C. Beyond the cell surface: new mechanisms of receptor function. Biochem. Biophys. Res. Commun. 2010, 396:24-27.
28. Kim W., Mohney R., Wilson B., Jeohn G., Liu B., Hong J. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 2000, 20:6309-6316.
29. Kurkowska-Jastrzebska I., Bałkowiec-Iskra E., Joniec I., Litwin T., Członkowski A., Członkowska A. Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinson's disease. Neuroscience 2005, 131:247-254.
30. Kurkowska-Jastrzebska I., Bałkowiec-Iskra E., Ciesielska A., Joniec I., Cudna A., Zaremba M., et al. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease. Int. Immunopharmacol. 2009, 9:781-791.
31. Lee S., Benveniste E. Adhesion molecule expression and regulation on cells of the central nervous system. J. Neuroimmunol. 1999, 98:77-88.
32. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
33. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
34. Miklossy J., Doudet D., Schwab C., Yu S., McGeer E., McGeer P. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 2006, 197:275-283.
35. Paratcha G., Ledda F., Ibáñez C. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 2003, 113:867-879.
36. Paxinos G., Watson C. The Rat brain in stereotaxic coordinates 1998, Academic Press, San Diego.
37. Rabchevsky A.G., Degos J.D., Dreyfus P.A. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Research 1999, 832:84-96.
38. Sherer T.B., Betarbet R., Kim J.H., Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett. 2003, 341:87-90.
39. Xu Y., Nygård M., Kristensson K., Bentivoglio M. Regulation of cytokine signaling and T-cell recruitment in the aging mouse brain in response to central inflammatory challenge. Brain Behav. Immun. 2010, 24:138-152.